Core Viewpoint - Aldeyra Therapeutics, Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding its drug candidate reproxalap during clinical trials [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from November 3, 2023, to March 16, 2026, with a deadline for participation set for May 29, 2026 [2]. - The complaint alleges that Aldeyra's positive statements about its clinical trials were unreliable and that the results of reproxalap were inconsistent [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments, although such an appointment is not necessary to recover losses [2][3].

Core Viewpoint - ONWARD Medical N.V. is set to hold its 2026 Annual General Meeting (AGM) on May 13, 2026, in Amsterdam, focusing on key resolutions and company developments in neurotechnology for spinal cord injuries and movement disabilities [1][2]. Company Overview - ONWARD Medical is a leading neurotechnology company that develops therapies aimed at restoring movement, function, and independence for individuals with spinal cord injuries (SCI) and other movement disabilities [3]. - The company has developed ARC Therapy, which has received 10 Breakthrough Device Designations from the FDA, and its ARC-EX System is commercially available in the US and Europe [3]. - An investigational implantable system, ARC-IM, is under development to address unmet needs such as blood pressure instability post-spinal cord injury and can integrate with brain-computer interfaces (BCI) and artificial intelligence (AI) for thought-driven movement restoration [3]. AGM Resolutions - The AGM will discuss the annual report and accounts for the financial year 2025, including the implementation of the compensation policy and the dividend and reservation policy [4]. - Key voting items include the release of directors from liability for their duties during the financial year 2025, the appointment and re-appointment of non-executive directors, and the delegation of authority to issue ordinary shares and acquire shares [4].

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Insights - AskBio Inc. has completed the randomization of the last participant in its Phase 2 clinical trial, GenePHIT, for AB-1002, a gene therapy aimed at treating heart failure with reduced ejection fraction (HFrEF) [1][2][3] Company Overview - AskBio Inc. is a gene therapy company wholly owned by Bayer AG, focusing on developing innovative therapies for various diseases, including heart failure [1][9] - The company has a diverse clinical pipeline targeting conditions related to cardiovascular, central nervous system, and neuromuscular diseases, with over 600 patents in gene therapy technologies [9] Clinical Trial Details - GenePHIT trial includes 173 participants and aims to evaluate the safety and efficacy of AB-1002, administered via a single intracoronary infusion [2][8] - Initial results from the trial are expected in the first half of 2027, marking a significant milestone in the development of new treatments for heart failure [2][7] Heart Failure Context - Heart failure is a growing public health issue, affecting an estimated 64 million people globally, with high mortality and morbidity rates despite existing treatments [3][5] - The need for innovative therapies in this area is critical, as the prevalence of heart failure continues to rise [2][3]

Company Announcement - Alstom has appointed Martin Sion as its new CEO, effective immediately [1] - The former CEO, Henri Poupart-Lafarge, has decided not to seek a further term [2]

Core Insights - Klépierre has filed its universal registration document for the fiscal year 2025 with the French financial market authority, AMF, under registration number D.26-0185 [2] - The document is available in both French and English and can be accessed online or requested via mail or email [3] Company Overview - Klépierre is a leading European shopping mall operator, focusing exclusively on continental Europe, with a portfolio valued at €21.2 billion as of December 31, 2025 [5] - The company operates shopping centers in over 10 countries in continental Europe, attracting more than 720 million visitors annually [5] - Klépierre is a French REIT (SIIC) and is included in the CAC Next 20 and EPRA Euro Zone Indexes, as well as various ethical indexes, highlighting its commitment to sustainable development [5] Upcoming Events - Key dates include the first quarter 2026 trading update on May 7, 2026, the Annual General Meeting on the same day, and the final dividend payment scheduled for July 7, 2026 [3]

Core Viewpoint - Oracle's stock surged by approximately 5-6% following the announcement of significant job cuts as part of a restructuring strategy aimed at enhancing its focus on artificial intelligence and cloud infrastructure [1][10]. Group 1: Job Cuts and Restructuring - The layoffs are part of Oracle's aggressive strategy to pivot towards AI, with reports indicating that over 12,000 jobs may have been cut in India alone, making it one of the hardest-hit regions [2][11]. - The company has filed notices confirming job reductions in the United States, with indications that the scale of layoffs could expand further [11]. Group 2: Market Reaction - Despite the negative perception associated with large-scale layoffs, investors reacted positively, anticipating that workforce reductions will lead to improved cost efficiency and help mitigate the heavy spending required for AI infrastructure [6][11]. - Market participants are focusing on the long-term growth potential of Oracle's AI and cloud businesses rather than the immediate disruptions caused by layoffs [7][10]. Group 3: Industry Context - Oracle's strategic shift aligns with a broader trend in the technology sector, where companies are reducing headcount while simultaneously increasing investments in AI capabilities [9][11]. - The company is reallocating significant capital towards building data centers and next-generation computing infrastructure to compete with major cloud players, although this shift may lead to short-term financial pressures due to increased capital expenditure and restructuring costs [8][11].

Core Insights - Ericsson will publish its financial report for Q1 2026 on April 17, 2026, at approximately 7:00 AM CEST [1][5] - A live video webcast for analysts, investors, and journalists will take place at 9:00 AM CEST on the same day [4][5] - The webcast will be available on-demand after the event on Ericsson's website [2] Company Information - Ericsson has been a pioneer in communication technology for 150 years, providing mobile communication and connectivity solutions for service providers and enterprises [2] - The company aims to make the digital world of tomorrow a reality through collaboration with customers and partners [2]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - Mkango Resources Limited successfully completed a fundraise of £12.5 million, which was oversubscribed and increased from the initial target of £10 million, reflecting strong demand from investors [6][20]. Fundraise Details - The fundraise generated gross proceeds of approximately £12.5 million (around C$23.0 million) before expenses [6][7]. - A total of 37,878,788 new Common Shares were conditionally placed at a price of 33 pence (C$0.606375) per share [7]. - The breakdown of the fundraise includes: - 30,909,154 new Common Shares from the Placing, raising approximately £10.2 million (C$18.7 million) - 636,300 new Common Shares from the LIFE Offering, raising approximately £0.2 million (C$0.4 million) - 3,030,303 new Common Shares from the Retail Offer, raising approximately £1.0 million (C$1.8 million) - 3,303,031 new Common Shares from the Subscription, raising approximately £1.1 million (C$2.0 million) [8]. Use of Proceeds - The net proceeds from the fundraise will be utilized for: - Acquisition of a synergistic German magnet business: £4,330,000 (C$7,956,375) - Capital expenditure for German operations: £3,950,000 (C$7,258,125) - Capital expenditure for UK operations: £2,200,000 (C$4,042,500) - Working capital: £2,020,000 (C$3,711,750) [15][16]. Market Context - The fundraise is seen as a strong endorsement of Mkango's strategy and long-term opportunities in the rare earths supply chain, particularly in light of challenging market conditions [20]. - The company aims to strengthen its balance sheet and advance growth initiatives in the UK, Germany, and beyond [20]. Share Capital and Trading - Following the admission of the Offer Shares, the total issued share capital will consist of 387,110,284 shares [21]. - Applications will be made for the Offer Shares to be admitted to trading on AIM and the TSX-V, with expected trading commencement on April 10, 2026 [11].